Product Description
Mechanisms of Action: GLP-1 Stimulant
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Hangzhou Sino-American East China Pharmaceutical Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 22
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Obesity|Overweight|Type 2 Diabetes
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06885021 |
HDM1002-301 | P3 |
Not yet recruiting |
Overweight|Obesity |
2026-05-30 |
2025-03-20 |
||
NCT07193459 |
HDM1002-302 | P3 |
Recruiting |
Type 2 Diabetes |
2026-10-10 |
2025-09-26 |
||
NCT07331389 |
HDM1002-111 | P1 |
Recruiting |
Overweight |
2026-01-12 |
50% |
2026-01-10 |
Primary Endpoints |
CTR20242942 |
CTR20242942 | P1 |
Completed |
Overweight |
2025-03-07 |
2026-05-10 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20243779 |
CTR20243779 | P1 |
Completed |
Overweight |
2025-02-26 |
2026-05-10 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06601517 |
HDM1002-106 | P1 |
Not yet recruiting |
Overweight |
2025-02-01 |
2024-09-24 |
Primary Endpoints |
|
CTR20243553 |
CTR20243553 | P1 |
Completed |
Overweight |
2025-01-10 |
2025-06-01 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06520540 |
HDM1002-103 | P1 |
Not yet recruiting |
Overweight |
2024-11-30 |
2024-07-26 |
Primary Endpoints|Treatments |
|
NCT06562088 |
HDM1002-105 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-11-19 |
2024-08-21 |
Primary Endpoints|Treatments |
|
NCT06608329 |
HDM1002-108 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-11-01 |
2024-09-24 |
Primary Endpoints|Treatments |
|
CTR20242410 |
CTR20242410 | P1 |
Completed |
Overweight |
2024-10-28 |
2025-06-22 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06576401 |
HDM1002-104 | P1 |
Recruiting |
Healthy Volunteers |
2024-10-01 |
2024-09-05 |
Primary Endpoints |
|
CTR20243056 |
CTR20243056 | P1 |
Completed |
Overweight |
2024-09-10 |
2025-06-13 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20233390 |
CTR20233390 | P1 |
Completed |
Overweight |
2024-04-12 |
2025-06-22 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20260711 |
CTR20260711 | P1 |
Active, not recruiting |
Type 2 Diabetes|Overweight |
None |
2026-05-10 |
||
CTR20251572 |
CTR20251572 | P1 |
Recruiting |
Overweight|Obesity|Type 2 Diabetes |
None |
2025-05-17 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20242121 |
CTR20242121 | P2 |
Completed |
Type 2 Diabetes |
2025-06-27 |
2026-05-10 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06481085 |
HDM1002-202 | P2 |
Completed |
Type 2 Diabetes |
2025-05-30 |
2025-07-29 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20241151 |
CTR20241151 | P2 |
Completed |
Overweight |
2024-09-19 |
2025-06-22 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT07594847 |
HDM1002-110 | P1 |
Recruiting |
Healthy Volunteers |
2026-09-25 |
88% |
2026-05-20 |
Primary Endpoints|Treatments |
NCT07082114 |
HDM1002-303 | P3 |
Recruiting |
Type 2 Diabetes |
2027-02-16 |
2025-07-25 |
Primary Endpoints|Treatments |
|
NCT06985615 |
HDM1002-109 | P1 |
Recruiting |
Healthy Volunteers |
2026-01-14 |
2025-05-23 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/26/2024 |
News Article |
HUADONG MEDICINE Announces Positive Phase I Results for Innovative Oral Small Molecule GLP-1 Receptor Agonist HDM1002 |
|
06/26/2024 |
News Article |
HUADONG MEDICINE Announces Positive Phase I Results for Innovative Oral Small Molecule GLP-1 Receptor Agonist HDM1002 |